Mounjaro Users' Weight-Loss Plateau Spells Trouble: Study Reveals Reversal of Health Benefits Upon Dose Cessation.
Researchers have discovered that individuals who discontinue using the weight-loss medication Mounjaro experience not only a rebound in weight, but also a reversal of other health benefits they had achieved during treatment. The biotech giant Eli Lilly's top-selling medication has been touted for its remarkable ability to facilitate significant body weight reductions - up to 20% - following 72-week treatment.
A study published recently in the journal Jama Internal Medicine analyzed data from participants who initially experienced substantial weight loss while undergoing Mounjaro treatment, alongside diet and exercise support. The trial involved 308 patients who lost at least 10% of their body weight over a 36-week period before switching to a placebo for an additional 52 weeks.
Surprisingly, the findings revealed that nearly 82% of participants regained 25% or more of their initial weight reduction just one year after stopping Mounjaro. Furthermore, greater weight regain was associated with a notable reversal in other health benefits, including waist circumference, levels of "bad" cholesterol, blood pressure, and blood glucose levels.
"The findings are not surprising, as excess weight is a well-established driver of elevated blood pressure and impaired glucose control," noted Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow. "Consequently, when weight lost through therapeutic interventions is regained, these cardiometabolic risk factors typically rise in proportion to the speed and extent of weight regain."
The study emphasizes the importance of long-term maintenance of weight reduction through lifestyle intervention and obesity management medications to sustain cardiometabolic benefits and improved health-related quality of life. It also highlights the potential risks of relying solely on medication for weight loss, particularly when it can lead to poorer dietary habits and a lack of motivation to engage in regular physical activity.
While researchers acknowledge that further trials are necessary to confirm these findings, they underscore the need for caution and careful consideration when interpreting data related to weight-loss medications and their effects on health.
Researchers have discovered that individuals who discontinue using the weight-loss medication Mounjaro experience not only a rebound in weight, but also a reversal of other health benefits they had achieved during treatment. The biotech giant Eli Lilly's top-selling medication has been touted for its remarkable ability to facilitate significant body weight reductions - up to 20% - following 72-week treatment.
A study published recently in the journal Jama Internal Medicine analyzed data from participants who initially experienced substantial weight loss while undergoing Mounjaro treatment, alongside diet and exercise support. The trial involved 308 patients who lost at least 10% of their body weight over a 36-week period before switching to a placebo for an additional 52 weeks.
Surprisingly, the findings revealed that nearly 82% of participants regained 25% or more of their initial weight reduction just one year after stopping Mounjaro. Furthermore, greater weight regain was associated with a notable reversal in other health benefits, including waist circumference, levels of "bad" cholesterol, blood pressure, and blood glucose levels.
"The findings are not surprising, as excess weight is a well-established driver of elevated blood pressure and impaired glucose control," noted Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow. "Consequently, when weight lost through therapeutic interventions is regained, these cardiometabolic risk factors typically rise in proportion to the speed and extent of weight regain."
The study emphasizes the importance of long-term maintenance of weight reduction through lifestyle intervention and obesity management medications to sustain cardiometabolic benefits and improved health-related quality of life. It also highlights the potential risks of relying solely on medication for weight loss, particularly when it can lead to poorer dietary habits and a lack of motivation to engage in regular physical activity.
While researchers acknowledge that further trials are necessary to confirm these findings, they underscore the need for caution and careful consideration when interpreting data related to weight-loss medications and their effects on health.